A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the efficacy and safety of camrelizumab given
concomitantly with chemoradiation in participants with unresectable, locally advanced head
and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in
addition to chemoradiation, the standard treatment for LA-HNSCC.